Potential With Cabozantinib Plus Nivolumab in Advanced RCC
Bradley McGregor, MD, clinical director, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, senior physician, instructor in medicine, Harvard Medical School, discusses the goals of the phase III CheckMate-9ER trial, which is evaluating cabozantinib combined with nivolumab in previously untreated patients with advanced or metastatic renal cell carcinoma (RCC).
Bradley McGregor, MD, clinical director, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, senior physician, instructor in medicine, Harvard Medical School, discusses the goals of the phase III CheckMate-9ER trial, which is evaluating cabozantinib (Cabometyx) combined with nivolumab (Opdivo) in previously untreated patients with advanced or metastatic renal cell carcinoma (RCC).
There has been a revolution in RCC treatment over the last couple of years, starting with the immunotherapy combination of nivolumab and ipilimumab (Yervoy) in the CheckMate-214 trial. Cabozantinib is an intriguing multikinase inhibitor that has also demonstrated benefit in patients with both treatment-naïve and previously treated disease, McGregor says.
Building upon the activity with these types of agents in the frontline setting, the CheckMare-9ER trial is looking at the combination of cabozantinib and nivolumab compared with sunitinib (Sutent) to determine if the combination can improve response rates and outcomes in the frontline setting.
Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCC
March 1st 2024In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.
Listen
PTCy Offers New Hope for Mismatched Stem Cell Transplants in Leukemia, MDS
April 13th 2024Jeff Auletta, MD, discussed how PTCy-based graft-vs-host disease prophylaxis offers a promising approach for expanding access to successful cell transplantation regardless of donor match or patient ethnicity.
Read More
Beyond the First-Line: Economides on Advancing Therapies in RCC
February 1st 2024In our 4th episode of Emerging Experts, Minas P. Economides, MD, unveils the challenges and opportunities for renal cell carcinoma treatment, focusing on the lack of therapies available in the second-line setting.
Listen
